Saint Louis University Institute for Drug and Biotherapeutic Innovation (IDBI)

Therapeutic Approaches: Biologics, Small Molecules, Vaccines, Biomarkers, Gene Therapy, Drug Delivery, on, on, Biomaterials, Biomaterials, Covid-19, on, Biomaterials, Biomaterials

Therapeutic Areas of Expertise: Immunology, Infectious Diseases, Metabolic Disorders, Neurological Disorders, Oncology, Pain, Regenerative Medicine, Virology, Hepatic Diseases, Orphan Diseases, Musculoskeletal disorders

Center/Program Highlights:


The IDBI is a decentralized, collaborative institute whose mission is to promote the translation of research projects at Saint Louis University through drug discovery and pre-clinical development. The IDBI achieves this through four main areas:

  • Facilitating external sponsorship of promising translational research

  • Education of members and students on drug discovery and development

  • Provide drug discovery consultations, seed grants, and other tools to members to advance translational projects

  • Facilitate intra and inter-institutional translational collaborations

The IDBI operates physical and virtual service cores to provide access to key drug development steps such as assay development, compound screening/counter screening, ADME/PK, and medicinal chemistry drug optimization. The broader SLU research community also offers access to world class vivarium facilities, and world leaders in vaccine and therapeutic clinical trials through the Center for Vaccine Development.

Sources of Funding: Philanthropy, Industry Partnerships, Disease Foundations, University, Federal/State,


Institutional Affiliation(s): St. Louis University (SLU)

SLU Institute for Drug & Biotherapeutic Innov
221 North Grand Blvd.
St. Louis
Missouri, 63103
United States

Center/Program Start Date: 2017

Number of Employees: 70